$BCRX BRUSSELS (Reuters) - The European Union has agreed to pay more than 1 billion euros ($1.2 billion) to Gilead (GILD.O) for a six-month supply of its antiviral drug remdesivir, shortly before the publication of final results of the biggest trial of the COVID-19 medication. Wondered why All these hires in Europe make some sense now probably soon we will be hearing some good news for Gali from Europe
  • 5
5 Likes